Quick Answer
Processa Pharmaceuticals, Inc. reported Net Income of -$13.56 million for fiscal year 2025.
Processa Pharmaceuticals, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$13.56M | -14.5% |
| 2024 | -$11.85M | -6.6% |
| 2023 | -$11.12M | +59.4% |
| 2022 | -$27.42M | -140.0% |
| 2021 | -$11.43M | +20.7% |
| 2020 | -$14.41M | -329.3% |
| 2019 | -$3.36M | +10.8% |
| 2018 | -$3.77M | -102.8% |
| 2017 | -$1.86M | +3.2% |
| 2016 | -$1.92M | +42.8% |
| 2015 | -$3.35M | +25.9% |
| 2014 | -$4.53M | -47.5% |
| 2013 | -$3.07M | -25.7% |
| 2012 | -$2.44M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$3.44M | -1.5% | +12.6% |
| June 30, 2025 | -$3.93M | -30.7% | -38.8% |
| March 31, 2025 | -$2.83M | -4.0% | +16.3% |
| September 30, 2024 | -$3.38M | -62.6% | -12.4% |
| June 30, 2024 | -$3.01M | -15.2% | -10.4% |
| March 31, 2024 | -$2.73M | +32.2% | -31.0% |
| September 30, 2023 | -$2.08M | +65.4% | +20.3% |
| June 30, 2023 | -$2.61M | +49.4% | +35.0% |
- Processa Pharmaceuticals, Inc. showed a decrease of -14.5% in Net Income compared to the prior fiscal year.
- Over the 2012–2025 period, Processa Pharmaceuticals, Inc.’s net income has declined by 455.8% (from -$2.44 million to -$13.56 million).
- The most recent figure is from Processa Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: